Last $123.29 USD
Change Today -0.84 / -0.68%
Volume 643.4K
TMO On Other Exchanges
New York
As of 12:20 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

thermo fisher scientific inc (TMO) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/14 - $127.63
52 Week Low
10/9/13 - $89.71
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

thermo fisher scientific inc (TMO) Details

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics in the United States and internationally. It operates in three segments: Analytical Technologies; Specialty Diagnostics; and Laboratory Products and Services. The Analytical Technologies segment offers instruments, reagents, consumables, software, and services for a range of applications in the laboratory, on the production line, and in the field. This segment serves pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as the clinical laboratory. The Specialty Diagnostics segment provides various diagnostic test kits, reagents, culture media, instruments, and associated products that are used by customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. This segment offers blood-test systems to support the clinical diagnosis and monitoring of allergy, asthma, and autoimmune diseases; liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, calibrators, controls, and calibration verification fluids; human leukocyte antigen typing and testing for the organ transplant; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; and products for cancer diagnosis and medical research in histology, cytology, and hematology applications. The Laboratory Products and Services segment offers laboratory equipment, including sample preparation and preservation equipment, cold storage equipment, centrifugation products, biological safety cabinets, temperature control products, water analysis instruments, and other laboratory equipment, as well as laboratory consumables, research and safety market solutions, and biopharma services. The company was founded in 1956 and is headquartered in Waltham, Massachusetts.

50,000 Employees
Last Reported Date: 02/27/14
Founded in 1956

thermo fisher scientific inc (TMO) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $1.1M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $653.7K
Executive Vice President and President of Lab...
Total Annual Compensation: $697.9K
Senior Vice President and President of Analyt...
Total Annual Compensation: $514.1K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $622.6K
Compensation as of Fiscal Year 2013.

thermo fisher scientific inc (TMO) Key Developments

Thermo Fisher Scientific Appoints New Members to Scientific Advisory Board

Thermo Fisher Scientific Inc. has appointed three new members to its Scientific Advisory Board: Dr. Andrea Califano, Dr. Arnold J. Levine and Dr. Aviv Regev. Dr. Califano is the founding chairman of the department of systems biology at Columbia University, and he currently serves on the board of scientific advisors of the National Cancer Institute. He is also professor of biomedical informatics at Columbia University. Dr. Levine is professor emeritus of systems biology at the Institute for Advanced Study in Princeton, N.J. and professor of pediatrics and of biochemistry with the Robert Wood Johnson Medical School at Rutgers, the State University of New Jersey. Dr. Regev is a core member of the Broad Institute and an associate professor of biology at the Massachusetts Institute of Technology. She is also an investigator at the Howard Hughes Medical Institute.

Thermo Fisher Scientific Introduces New Gene Editing Tool Kits

Thermo Fisher Scientific, Inc. has introduced GeneArt CRISPR products, the company's new tool kits to make specific changes to DNA in a variety of cells. GeneArt CRISPR products from Thermo Fisher Scientific leverage the type II CRISPR (clustered regulatory interspaced short palindromic repeats)/Cas9 system for genome editing. This is an RNA guided DNA endonuclease system that has two key components, the Cas9 protein that serves as an DNA endonuclease and a non-coding RNA component called guide RNA that confers target specificity. The CRISPR/Cas9 system works in conjunction with endogenous repair mechanisms to alter DNA within a cell. GeneArt CRISPR Nuclease mRNA is ready to transfect or microinject wild type Cas9 in mRNA format. The mRNA format is best for multiplexed screening of gRNA sequences, applications that require delivery by microinjection, and easier dosage optimization of Cas9 protein to gRNA in the cell. Cas9 mRNA is co-transfected with 1 or more custom GeneArt CRISPR Strings DNA encoding target-specific guide RNA (gRNA) or in vitro transcribed gRNA which removes promoter constraints and is a better option for difficult to transfect cells such as induced pluripotent stem cells, or iPSCs. The GeneArt CRISPR Nuclease Vector Kits offer reporter and enrichment tags for tracking gene editing experiments and are great for cloning and re-use of confirmed gRNA sequences. The GeneArt CRISPR Nuclease Vector with CD4 Enrichment is a vector system for expression of the functional components of the CRISPR/Cas9 technology with a CD4 reporter. The CD4 reporter offers magnetic bead-based sorting/enrichment of Cas9 & CRISPR expressing cells using Dynabeads CD4 magnetic beads. Transfection efficiency can also be tracked using anti-CD4 fluorescent antibodies. The GeneArt CRISPR Nuclease Vector with OFP Reporter is a similar expression vector system with an orange fluorescent protein (OFP) reporter. The OFP reporter allows for fluorescence-based tracking of transfection efficiency, as well as FACS-based sorting/enrichment of Cas9 and CRISPR expressing cells. GeneArt CRISPRs can be used with other gene editing tools, such as the GeneArt Genomic Detection Cleavage Kit, providing a complete solution for design of synthetic genes, circuits and detection.

Thermo Fisher Scientific Inc. Launches New Transcriptome RNA-Sequencing Solution

Thermo Fisher Scientific Inc. has launched Ion AmpliSeq Transcriptome Solution for the Ion Proton System, a next generation sequencing solution to obtain gene expression profiles from biobank samples. Its ability to draw gene expression profiles from just 10ng of RNA sets the Ion AmpliSeq Transcriptome Solution apart from other solutions in the market, and it is compatible with formalin-fixed, paraffin-embedded (FFPE) samples. This is critical to the needs of oncology and translational researchers. The Ion Ampliseq Solution also provides a faster and more cost-effective workflow without the sample manipulation required for microarrays or analytical complexity normally associated with whole transcriptome RNA-sequencing.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TMO:US $123.29 USD -0.84

TMO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $43.75 USD +0.06
Corning Inc $20.53 USD -0.22
Danaher Corp $79.58 USD +0.22
Safran SA €50.87 EUR -0.59
Solvay SA €122.60 EUR 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation TMO Industry Range
Price/Earnings 32.2x
Price/Sales 3.3x
Price/Book 2.4x
Price/Cash Flow 33.5x
TEV/Sales 2.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERMO FISHER SCIENTIFIC INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at